Pan-Cancer Characterization Identifies SLC19A1 as an Unfavorable Prognostic Marker and Associates It with Tumor Infiltration Features
- Yimin Pan 1, Zhichen Liu 2, Changwu Wu 1,3
- Yimin Pan 1, Zhichen Liu 2, Changwu Wu 1,3
- 1Department of Neurosurgery, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha 410008, China.
- 2Department of Orthopedics, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha 410008, China.
- 3National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China.
- 0Department of Neurosurgery, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha 410008, China.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Solute carrier family 19 member 1 (SLC19A1) is overexpressed in many cancers, linked to poor prognosis, immune suppression, and genomic instability. Targeting SLC19A1 may offer new cancer treatment strategies.
Area Of Science
- Oncology
- Immunology
- Molecular Biology
Background
- Solute carrier family 19 member 1 (SLC19A1) is identified as a transporter regulating immune signaling.
- Limited information exists on SLC19A1's role and mechanisms in diverse cancer types.
Purpose Of The Study
- To evaluate the role and mechanisms of SLC19A1 in various cancers.
- To assess SLC19A1's association with prognosis, tumor stemness, genome instability, and immune infiltration.
Main Methods
- Analysis of multi-omics data from a pan-cancer cohort.
- Evaluation of SLC19A1 expression and its correlation with clinical features.
- Immunofluorescence staining to validate SLC19A1 and M2 macrophage relationships.
- Web tools used to assess SLC19A1's association with treatment response.
Main Results
- SLC19A1 is overexpressed in multiple cancers, correlating with poor prognosis.
- High SLC19A1 levels are linked to increased genomic instability and immune suppression.
- SLC19A1 negatively correlates with CD8+ T-cell infiltration and positively with M2 macrophage infiltration.
- SLC19A1 is associated with chemotherapy and immunotherapy response.
Conclusions
- SLC19A1 serves as a novel unfavorable prognostic marker in cancer.
- SLC19A1 is closely associated with immune suppression and genomic instability.
- Further exploration of SLC19A1 as a therapeutic target is warranted for cancer treatment strategies.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.